Juvenile idiopathic arthritis

@article{Prakken2011JuvenileIA,
  title={Juvenile idiopathic arthritis},
  author={Berent Prakken and Salvatore Albani and Alberto Martini},
  journal={The Lancet},
  year={2011},
  volume={377},
  pages={2138-2149}
}
Juvenile idiopathic arthritis is a heterogeneous group of diseases characterised by arthritis of unknown origin with onset before age of 16 years. Pivotal studies in the past 5 years have led to substantial progress in various areas, ranging from disease classification to new treatments. Gene expression profiling studies have identified different immune mechanisms in distinct subtypes of the disease, and can help to redefine disease classification criteria. Moreover, immunological studies have… Expand
124 Citations
Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches
TLDR
An overview of advances in understanding of JIA pathogenesis focusing on aetiology, histopathology, immunological changes associated with disease activity, and best treatment options is provided. Expand
MicroRNAs in juvenile idiopathic arthritis: Can we learn more about pathophysiological mechanisms?
TLDR
Results published on miRNAs expression profiles in JIA patients are gathered with the aim to identify miRNA that can be used as diagnostic biomarkers and provide information on disease activity and progression and on common pathways potentially involved in disease pathophysiology. Expand
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis
TLDR
In the pivotal trials for IV and SC abatacept, either with or without MTX, both formulations demonstrated clinical efficacy, with a high proportion of patients achieving stringent clinical responses, as well as improvements in patient-reported outcomes and a favorable safety profile, particularly with regard to infections. Expand
Cardiovascular disease in Juvenile Idiopathic Arthritis.
TLDR
Overall, patients with systemic forms of JIA demonstrate an adverse lipid profile and early arterial changes relevant to accelerated arterial disease progression, and a holistic approach is recommended which includes CV risk factor monitoring and lifestyle modification as well as use of anti-inflammatory therapies with documented CV safety. Expand
Serum protein signatures differentiate paediatric autoimmune/inflammatory disorders.
TLDR
Serum samples were collected for the definition of disease sub-form specific cytokine and chemokine profiles to overcome issues around diagnostic approaches in the context of clinical overlap and simultaneous quantification of serum proteins in a panel format may provide an avenue for the diagnosis and monitoring of childhood autoimmune/inflammatory conditions. Expand
Are there new targets for juvenile idiopathic arthritis?
  • A. Martini
  • Medicine
  • Seminars in arthritis and rheumatism
  • 2019
TLDR
Novel potential targets for sJIA as well as for macrophage activation syndrome, its more severe complication, have therefore been investigated mainly in children. Expand
Juvenile Idiopathic Arthritis and the Hip
Juvenile idiopathic arthritis (JIA) is a group of heterogeneous conditions characterised by chronic inflammatory arthritis in children (<16 years), persisting for longer than 6 weeks, with no knownExpand
Serological screening for coeliac disease in patients with juvenile idiopathic arthritis.
  • Y. Şahin, S. Şahin, +5 authors O. Kasapcopur
  • Medicine
  • Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  • 2019
TLDR
The frequency of coeliac disease (CD) in patients with juvenile idiopathic arthritis (JIA) was assessed and it was found that CD in children with JIA was not found. Expand
Genetic architecture study of rheumatoid arthritis and juvenile idiopathic arthritis
TLDR
The identification of commonly associated genes and pathways may help in finding population at risk for both autoimmune diseases, as well as shed light on repositioning and designing drugs for both diseases. Expand
Systemic Juvenile Idiopathic Arthritis.
TLDR
Primary care providers have a crucial role in monitoring children with sJIA for disease-related complications and medication-related adverse events. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 150 REFERENCES
New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment.
TLDR
Current knowledge of pathophysiology and experiences in the treatment of SJIA, including application of recombinant anti-IL-1 receptor antagonist or anti- IL-6 receptor antibodies in patients resistant to conventional anti-inflammatory treatment are summarized. Expand
Using biology of disease to understand and guide therapy of JIA.
TLDR
Treatment strategies might focus on the induction of regulation in a more specific fashion, such as regulatory T cells, FoxP3, heat shock proteins, cytokines, chemokines and other key mediators of inflammation. Expand
Systemic JIA: new developments in the understanding of the pathophysiology and therapy.
TLDR
Consensus is emerging that sJIA should be viewed as an autoinflammatory syndrome rather than a classic auto-immune disease, and remarkable improvement has been observed with IL-1 and IL-6 targeted therapies. Expand
Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade
TLDR
Leukocyte transcriptional signatures can be used to distinguish SoJIA from other febrile illnesses and to assess response to therapy and availability of early diagnostic markers may allow prompt initiation of therapy and prevention of disabilities. Expand
Juvenile idiopathic arthritis: state of the art and future perspectives
TLDR
Despite a dramatic advance in the understanding of JIA categories, pathobiology and treatments, much remains to be done. Expand
Towards a New Clinico-Immunopathological Classification of Juvenile Inflammatory Arthritis
TLDR
A cross-sectional study in JIA patients with active, ankle-based disease using sonography to delineate the precise anatomical distribution of joint inflammation and determines whether clinical assessment of disease with respect to anatomical territory involvement as joint cavity-based or tenosynovial-based was accurate. Expand
Juvenile Idiopathic Arthritis
TLDR
This review focuses on recent advances in JIA, especially developments in its classification, validation of appropriate measures of holistic outcome, and the specific contribution of established and newer pharmacologic agents available for treating children and young people. Expand
Monitoring the long‐term safety of therapies for children with juvenile idiopathic arthritis: Time for a consolidated patient registry
TLDR
A consolidated registry with broad sponsorship by industry, federal agencies, research networks, and patient advocacy groups would offer a unique alternative approach to monitoring the long-term safety of pediatric rheumatology treatments, one that does not have the shortcomings of either of the two foregoing options. Expand
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
TLDR
It is shown that serum from SoJIA patients induces the transcription of innate immunity genes, including interleukin (IL)-1 in healthy peripheral blood mononuclear cells (PBMCs), and that this cytokine represents a target for therapy in this disease. Expand
Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease.
TLDR
The results support the hypothesis that patients with similar characteristics are currently classified into different JIA categories and the value of ANA positivity as a possible modifier of the current classification system deserves consideration. Expand
...
1
2
3
4
5
...